[go: up one dir, main page]

PE20091116A1 - Derivados de piridina y pirazina como inhibidores de tirosina quinasas - Google Patents

Derivados de piridina y pirazina como inhibidores de tirosina quinasas

Info

Publication number
PE20091116A1
PE20091116A1 PE2008001832A PE2008001832A PE20091116A1 PE 20091116 A1 PE20091116 A1 PE 20091116A1 PE 2008001832 A PE2008001832 A PE 2008001832A PE 2008001832 A PE2008001832 A PE 2008001832A PE 20091116 A1 PE20091116 A1 PE 20091116A1
Authority
PE
Peru
Prior art keywords
pyridine
inhibitors
pyridin
amine
tyrosine kinases
Prior art date
Application number
PE2008001832A
Other languages
English (en)
Inventor
Bernard Christophe Barlaam
Gilles Ouvry
Craig Steven Harris
Christine Marie Paul Lambert
Benedicte Delouvrie
Gary Fairley
Justin Fairfield Bower
Jon James Gordon Winter
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of PE20091116A1 publication Critical patent/PE20091116A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

REFERIDA A UN DERIVADO DE PIRIDINA O PIRAZINA DE FORMULA (I), DONDE W ES CH O N; J ES O O S; G1, G2, G3 Y G4 SON CH O N; EL ANILLO A ES FENILO, UN ANILLO HETEROARILO MONOCICLICO DE 5 O 6 MIEMBROS, UN SISTEMA DE ANILLOS BICICLICO DE 8, 9 O 10 MIEMBROS, ENTRE OTROS; n ES UN ENTERO DE 0 A 3; R3 ES H, HALOGENO, AMINO, CIANO, SULFAMOILO, ENTRE OTROS. SON COMPUESTOS PREFERIDOS: 3-(1,3-BENZOXAZOL-2-IL)-5-[1-(1-METILPIPERIDIN-4-IL)-1H-PIRAZOL-4-IL]PIRIDIN-2-AMINA, 3-(4-FLUORO-1,3-BENZOXAZOL-2-IL)-5-[1-(1-METILPIPERIDIN-4-IL)-1H-PIRAZOL-4-IL]PIRIDIN-2-AMINA, 3-(1,3-BENZOXAZOL-2-IL)-5-(3-METIL-1-PIPERIDIN-4-IL-1H-PIRAZOL-4-IL)PIRIDIN-2-AMINA, ENTRE OTROS. TAMBIEN ESTA REFERIDA A UNA COMPOSICION FARMACEUTICA. DICHOS COMPUESTOS SON INHIBIDORES DE LAS ENZIMAS TIROSINA QUINASAS TALES COMO Axl Y cMet, Y SON UTILES EN EL TRATAMIENTO DE DISTINTOS TIPOS DE CANCER
PE2008001832A 2007-10-25 2008-10-24 Derivados de piridina y pirazina como inhibidores de tirosina quinasas PE20091116A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP07301491 2007-10-25
EP07305005 2007-12-21
EP08305180 2008-05-19

Publications (1)

Publication Number Publication Date
PE20091116A1 true PE20091116A1 (es) 2009-08-29

Family

ID=40580139

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2008001832A PE20091116A1 (es) 2007-10-25 2008-10-24 Derivados de piridina y pirazina como inhibidores de tirosina quinasas

Country Status (18)

Country Link
US (1) US8017611B2 (es)
EP (1) EP2215085B1 (es)
JP (1) JP2011500778A (es)
KR (1) KR20100089090A (es)
CN (1) CN101910158A (es)
AR (1) AR069078A1 (es)
AT (1) ATE523508T1 (es)
AU (1) AU2008315746A1 (es)
CA (1) CA2703653A1 (es)
CL (1) CL2008003188A1 (es)
CO (1) CO6270364A2 (es)
EC (1) ECSP10010197A (es)
IL (1) IL205108A0 (es)
MX (1) MX2010004491A (es)
PE (1) PE20091116A1 (es)
TW (1) TW200920367A (es)
UY (1) UY31430A1 (es)
WO (1) WO2009053737A2 (es)

Families Citing this family (141)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102007026341A1 (de) 2007-06-06 2008-12-11 Merck Patent Gmbh Benzoxazolonderivate
DE102007032507A1 (de) 2007-07-12 2009-04-02 Merck Patent Gmbh Pyridazinonderivate
DE102007061963A1 (de) 2007-12-21 2009-06-25 Merck Patent Gmbh Pyridazinonderivate
JP2011511005A (ja) 2008-02-04 2011-04-07 オーエスアイ・フアーマスーテイカルズ・インコーポレーテツド ２−アミノピリジン系キナーゼ阻害薬
AR070317A1 (es) 2008-02-06 2010-03-31 Osi Pharm Inc Furo (3,2-c) piridina y tieno (3,2-c) piridinas
JP2011511078A (ja) * 2008-02-06 2011-04-07 レアド トヘラペウトイクス，インコーポレーテッド ポリ（ａｄｐリボース）ポリメラーゼ（ｐａｒｐ）のベンズオキサゾールカルボキサミド阻害剤
DE102008019907A1 (de) 2008-04-21 2009-10-22 Merck Patent Gmbh Pyridazinonderivate
DE102008028905A1 (de) 2008-06-18 2009-12-24 Merck Patent Gmbh 3-(3-Pyrimidin-2-yl-benzyl)-[1,2,4]triazolo[4,3-b]pyridazinderivate
RU2011123647A (ru) 2008-11-10 2012-12-20 Вертекс Фармасьютикалз Инкорпорейтед Соединения, полезные в качестве ингибиторов atr киназы
TWI396689B (zh) 2008-11-14 2013-05-21 Amgen Inc 作為磷酸二酯酶１０抑制劑之吡衍生物
TW201036966A (en) * 2008-12-02 2010-10-16 Du Pont Fungicidal heterocyclic compounds
AU2009327357C1 (en) 2008-12-19 2017-02-02 Vertex Pharmaceuticals Incorporated Pyrazine derivatives useful as inhibitors of ATR kinase
WO2010072295A1 (en) 2008-12-22 2010-07-01 Merck Patent Gmbh Novel polymorphic forms of 6-(1-methyl-1h-pyrazol-4-yl)-2-{3-[5-(2-morpholin-4-yl-ethoxy)-pyrimidin-2-yl]-benzyl}-2h-pyridazin-3-one dihydrogenphosphate and processes of manufacturing thereof
DE102009033208A1 (de) * 2009-07-15 2011-01-20 Merck Patent Gmbh Aminopyridinderivate
WO2011059388A1 (en) * 2009-11-13 2011-05-19 Astrazeneca Ab Oxazolo[4,5-c]pyridine substituted pyrazine
MX2012013082A (es) * 2010-05-12 2013-05-09 Vertex Pharma Derivados de 2-aminopiridina utiles como iinhibidores de cinasa atr.
EP2569289A1 (en) * 2010-05-12 2013-03-20 Vertex Pharmaceuticals Incorporated Pyrazines useful as inhibitors of atr kinase
WO2011143399A1 (en) 2010-05-12 2011-11-17 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of atr kinase
EP2569287B1 (en) 2010-05-12 2014-07-09 Vertex Pharmaceuticals Inc. Compounds useful as inhibitors of atr kinase
JP2013529200A (ja) 2010-05-12 2013-07-18 バーテックス ファーマシューティカルズ インコーポレイテッド Ａｔｒキナーゼ阻害剤として有用な化合物
KR20130066633A (ko) 2010-05-12 2013-06-20 버텍스 파마슈티칼스 인코포레이티드 Ａｔｒ 키나제의 억제제로서 유용한 화합물
UY33452A (es) 2010-06-16 2012-01-31 Bayer Schering Pharma Ag Triazolopiridinas sustituidas
MX2013000103A (es) 2010-06-23 2013-06-13 Vertex Pharma Derivados de pirrolo-pirazina utiles como inhibidores de cinasa art.
US20130315895A1 (en) 2010-07-01 2013-11-28 Takeda Pharmaceutical Company Limited COMBINATION OF A cMET INHIBITOR AND AN ANTIBODY TO HGF AND/OR cMET
WO2012088266A2 (en) 2010-12-22 2012-06-28 Incyte Corporation Substituted imidazopyridazines and benzimidazoles as inhibitors of fgfr3
JP5970003B2 (ja) * 2011-03-04 2016-08-17 ローカス ファーマシューティカルズ インコーポレイテッド アミノピラジン化合物
CN102718745A (zh) * 2011-03-30 2012-10-10 中国科学院上海药物研究所 新型胺基吡啶类化合物、其制备方法、包含此类化合物的药物组合物及其用途
WO2012138809A1 (en) * 2011-04-05 2012-10-11 Dawei Zhang Heterocyclic compounds as kinase inhibitors
CA2832100A1 (en) 2011-04-05 2012-10-11 Vertex Pharmaceuticals Incorporated Aminopyrazine compounds useful as inhibitors of tra kinase
JP6050335B2 (ja) 2011-05-23 2016-12-21 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ チアゾール誘導体
US9273029B2 (en) 2011-05-23 2016-03-01 Merck Patent Gmbh Pyridine-and pyrazine derivatives
WO2012178124A1 (en) 2011-06-22 2012-12-27 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of atr kinase
EP2723746A1 (en) 2011-06-22 2014-04-30 Vertex Pharmaceuticals Inc. Compounds useful as inhibitors of atr kinase
EP2723745A1 (en) 2011-06-22 2014-04-30 Vertex Pharmaceuticals Inc. Compounds useful as inhibitors of atr kinase
EP2739617A4 (en) * 2011-07-27 2015-01-28 Nanjing Allgen Pharma Co Ltd SPIROCYCLIC MOLECULES AS PROTEIN KINASE INHIBITORS
DE102011112978A1 (de) 2011-09-09 2013-03-14 Merck Patent Gmbh Benzonitrilderivate
CN103957917A (zh) 2011-09-30 2014-07-30 沃泰克斯药物股份有限公司 用atr抑制剂治疗胰腺癌和非小细胞肺癌
CA3124539A1 (en) 2011-09-30 2013-04-04 Vertex Pharmaceuticals Incorporated Process for making 4-[chloro-n-hydroxycarbonimidoyl]phenyl derivative
EP2751088B1 (en) 2011-09-30 2016-04-13 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of atr kinase
US8853217B2 (en) 2011-09-30 2014-10-07 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of ATR kinase
WO2013049722A1 (en) 2011-09-30 2013-04-04 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of atr kinase
CN103087050A (zh) * 2011-10-28 2013-05-08 山东轩竹医药科技有限公司 芳基激酶抑制剂
EP2776421A1 (en) 2011-11-09 2014-09-17 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of atr kinase
US8841449B2 (en) 2011-11-09 2014-09-23 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of ATR kinase
EP2776429A1 (en) 2011-11-09 2014-09-17 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of atr kinase
EP2776420A1 (en) 2011-11-09 2014-09-17 Vertex Pharmaceuticals Incorporated Pyrazine compounds useful as inhibitors of atr kinase
US8841337B2 (en) 2011-11-09 2014-09-23 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of ATR kinase
DE102011119127A1 (de) 2011-11-22 2013-05-23 Merck Patent Gmbh 3-Cyanaryl-1H-pyrrolo[2.3-b]pyridin-Derivate
NZ627586A (en) 2012-01-31 2016-08-26 Daiichi Sankyo Co Ltd Pyridone derivatives
LT2812337T (lt) 2012-02-09 2016-11-25 Merck Patent Gmbh Furo[3,2-b]piridino dariniai, kaip tbk1 ir ikk inhibitoriai
WO2013148537A1 (en) * 2012-03-29 2013-10-03 Ning Xi Substituted spirobicyclic compounds and methods of use
US20140044802A1 (en) 2012-04-05 2014-02-13 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of atr kinase and combination therapies thereof
US9096579B2 (en) 2012-04-20 2015-08-04 Boehringer Ingelheim International Gmbh Amino-indolyl-substituted imidazolyl-pyrimidines and their use as medicaments
WO2013162061A1 (ja) * 2012-04-26 2013-10-31 第一三共株式会社 二環性ピリミジン化合物
UA125503C2 (uk) 2012-06-13 2022-04-13 Інсайт Холдинґс Корпорейшн Заміщені трициклічні сполуки як інгібітори fgfr
KR101245559B1 (ko) * 2012-06-29 2013-03-22 한국화학연구원 신규 다중치환 벤즈옥사졸로 치환된 피리딘 유도체 또는 이의 약학적으로 허용가능한 염, 이의 제조방법 및 이를 유효성분으로 함유하는 이상세포 성장 질환의 예방 및 치료용 약학적 조성물
WO2014026125A1 (en) 2012-08-10 2014-02-13 Incyte Corporation Pyrazine derivatives as fgfr inhibitors
EP2904406B1 (en) 2012-10-04 2018-03-21 Vertex Pharmaceuticals Incorporated Method for measuring atr inhibition mediated increases in dna damage
EP2909202A1 (en) 2012-10-16 2015-08-26 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of atr kinase
RS64234B1 (sr) 2012-12-07 2023-06-30 Vertex Pharma Pirazolo[1,5-a]pirimidini korisni kao inhibitori atr kinaze za lečenje kancera
US9266892B2 (en) 2012-12-19 2016-02-23 Incyte Holdings Corporation Fused pyrazoles as FGFR inhibitors
EP2945938B1 (en) 2013-01-18 2018-03-07 F. Hoffmann-La Roche AG 3-substituted pyrazoles and use as dlk inhibitors
CA2897279C (en) 2013-01-23 2020-12-29 Astrazeneca Ab Aminopyrazine derivatives and pharmaceutical compositions thereof for use in the treatment of cancer
AU2014211856C1 (en) * 2013-02-02 2018-04-12 Centaurus Biopharma Co., Ltd. Substituted 2-aminopyridine protein kinase inhibitor
EP2970311A4 (en) 2013-03-14 2016-11-23 Brigham & Womens Hospital BMP HEMMER AND METHOD OF USE THEREOF
US9663519B2 (en) 2013-03-15 2017-05-30 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of ATR kinase
WO2014172644A2 (en) 2013-04-19 2014-10-23 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
WO2015077375A1 (en) 2013-11-20 2015-05-28 Signalchem Lifesciences Corp. Quinazoline derivatives as tam family kinase inhibitors
KR102398473B1 (ko) 2013-11-27 2022-05-16 시그널켐 라이프사이언시즈 코포레이션 Tam 패밀리 키나제 억제제로서의 아미노피리딘 유도체
SI3077397T1 (sl) 2013-12-06 2020-02-28 Vertex Pharmaceuticals Inc. 2-amino-6-fluoro-N-(5-fluoro-piridin-3-IL)pirazolo(1,5-A)pirimidin-3- karboksamidna spojina, koristna kot inhibitor kinaze ATR, njena priprava, različne trdne oblike in njeni radioaktivno označeni derivati
EP3122355A4 (en) * 2014-03-26 2017-08-09 The Brigham and Women's Hospital, Inc. Compositions and methods for inhibiting bmp
MX2016013981A (es) 2014-04-24 2016-11-15 Novartis Ag Derivados de amino-piridina como inhibidores de fosfatidil-inositol-3-cinasa.
KR20160141855A (ko) 2014-04-24 2016-12-09 노파르티스 아게 포스파티딜이노시톨 3-키나제 억제제로서의 아미노 피라진 유도체
KR20160141856A (ko) 2014-04-24 2016-12-09 노파르티스 아게 포스파티딜이노시톨 3-키나제 억제제로서의 피라진 유도체
SG11201610197XA (en) 2014-06-05 2017-01-27 Vertex Pharma Radiolabelled derivatives of a 2-amino-6-fluoro-n-[5-fluoro-pyridin-3-yl]- pyrazolo[1,5-a]pyrimidin-3-carboxamide compound useful as atr kinase inhibitor, the preparation of said compound and different solid forms thereof
NZ727399A (en) 2014-06-17 2022-07-29 Vertex Pharma Method for treating cancer using a combination of chk1 and atr inhibitors
TWI690525B (zh) 2014-07-07 2020-04-11 日商第一三共股份有限公司 具有四氫吡喃基甲基之吡啶酮衍生物及其用途
US10513521B2 (en) 2014-07-15 2019-12-24 The Brigham And Women's Hospital, Inc. Compositions and methods for inhibiting BMP
US9359336B2 (en) 2014-10-09 2016-06-07 Allergan, Inc. Heterocycle-substituted pyridyl benzothiophenes as kinase inhibitors
US10851105B2 (en) 2014-10-22 2020-12-01 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
TR201815071T4 (tr) * 2014-12-02 2018-11-21 Bayer Cropscience Ag Zararlılarla mücadele maddesi olarak bisiklik bileşikler.
ES2764299T3 (es) 2014-12-09 2020-06-02 Inst Nat Sante Rech Med Anticuerpos monoclonales humanos contra AXL
UA121669C2 (uk) 2015-02-20 2020-07-10 Інсайт Корпорейшн Біциклічні гетероцикли як інгібітори fgfr
MA41551A (fr) 2015-02-20 2017-12-26 Incyte Corp Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4
US9580423B2 (en) 2015-02-20 2017-02-28 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
WO2016135041A1 (en) 2015-02-26 2016-09-01 INSERM (Institut National de la Santé et de la Recherche Médicale) Fusion proteins and antibodies comprising thereof for promoting apoptosis
US9840503B2 (en) 2015-05-11 2017-12-12 Incyte Corporation Heterocyclic compounds and uses thereof
CA2990791A1 (en) * 2015-06-25 2016-12-29 Taiho Pharmaceutical Co., Ltd. Therapeutic agent for fibrosis
WO2017027717A1 (en) 2015-08-12 2017-02-16 Incyte Corporation Bicyclic fused pyrimidine compounds as tam inhibitors
WO2017035366A1 (en) 2015-08-26 2017-03-02 Incyte Corporation Pyrrolopyrimidine derivatives as tam inhibitors
HK1258570A1 (zh) 2015-09-30 2019-11-15 Vertex Pharmaceuticals Inc. 使用dna损伤剂及atr抑制剂的组合治疗癌症的方法
TW201718581A (zh) 2015-10-19 2017-06-01 英塞特公司 作為免疫調節劑之雜環化合物
LT3377488T (lt) * 2015-11-19 2023-01-10 Incyte Corporation Heterocikliniai junginiai, kaip imunomoduliatoriai
US20170174679A1 (en) 2015-12-22 2017-06-22 Incyte Corporation Heterocyclic compounds as immunomodulators
JP6885390B2 (ja) 2016-02-26 2021-06-16 小野薬品工業株式会社 Ａｘｌ阻害剤と免疫チェックポイント阻害剤とを組み合わせて投与することを特徴とする癌治療のための医薬
UA123785C2 (uk) 2016-03-28 2021-06-02 Інсайт Корпорейшн Сполуки піролотриазину як інгібітори tam
MA44860A (fr) 2016-05-06 2019-03-13 Incyte Holdings Corp Composés hétérocycliques utilisés comme immunomodulateurs
WO2017205464A1 (en) 2016-05-26 2017-11-30 Incyte Corporation Heterocyclic compounds as immunomodulators
HUE060256T2 (hu) 2016-06-20 2023-02-28 Incyte Corp Heterociklusos vegyületek mint immunmodulátorok
US20180016260A1 (en) 2016-07-14 2018-01-18 Incyte Corporation Heterocyclic compounds as immunomodulators
ES2941716T3 (es) 2016-08-29 2023-05-25 Incyte Corp Compuestos heterocíclicos como inmunomoduladores
KR102279347B1 (ko) * 2016-12-15 2021-07-21 한국생명공학연구원 피리딘계 화합물을 유효성분으로 함유하는 dyrk 관련 질환의 예방 또는 치료용 약학적 조성물
WO2018111049A1 (ko) * 2016-12-15 2018-06-21 한국생명공학연구원 피리딘계 화합물을 유효성분으로 함유하는 dyrk 관련 질환의 예방 또는 치료용 약학적 조성물
EP3558989B1 (en) 2016-12-22 2021-04-14 Incyte Corporation Triazolo[1,5-a]pyridine derivatives as immunomodulators
WO2018119221A1 (en) 2016-12-22 2018-06-28 Incyte Corporation Pyridine derivatives as immunomodulators
JP7303108B2 (ja) 2016-12-22 2023-07-04 インサイト・コーポレイション 免疫調節剤としての二環式複素芳香環化合物
WO2018119266A1 (en) 2016-12-22 2018-06-28 Incyte Corporation Benzooxazole derivatives as immunomodulators
EP3583943B1 (en) 2017-02-15 2024-09-18 Taiho Pharmaceutical Co., Ltd. Pharmaceutical composition
AR111960A1 (es) 2017-05-26 2019-09-04 Incyte Corp Formas cristalinas de un inhibidor de fgfr y procesos para su preparación
JP7156287B2 (ja) 2017-08-23 2022-10-19 小野薬品工業株式会社 Ａｘｌ阻害剤を有効成分として含むがん治療剤
MA50251A (fr) 2017-09-08 2021-06-02 Taiho Pharmaceutical Co Ltd Agent antitumoral et potentialisateur d'effet antitumoral
PL3687996T3 (pl) 2017-09-27 2022-02-21 Incyte Corporation Sole pochodnych pirolotriazyny użyteczne jako inhibitory tam
JP7223998B2 (ja) 2017-10-13 2023-02-17 小野薬品工業株式会社 Ａｘｌ阻害剤を有効成分として含む固形がん治療剤
CN117186108B (zh) * 2018-03-26 2025-08-19 诺华股份有限公司 布鲁顿酪氨酸激酶降解剂
ES3030010T3 (en) 2018-03-30 2025-06-26 Incyte Corp Heterocyclic compounds as immunomodulators
SI3788047T1 (sl) 2018-05-04 2024-11-29 Incyte Corporation Trdne oblike inhibitorja fgfr in postopki priprave le-teh
CN112566912A (zh) 2018-05-04 2021-03-26 因赛特公司 Fgfr抑制剂的盐
BR112020022936A2 (pt) 2018-05-11 2021-02-02 Incyte Corporation derivados de tetra-hidro-imidazo[4,5-c]piridina como imunomoduladores de pd-l1
EP4606432A3 (en) 2018-06-29 2025-10-29 Incyte Corporation Formulations of an axl/mer inhibitor
BR112021005606A2 (pt) 2018-09-29 2021-06-22 Novartis Ag processo de produção de um composto para inibir a atividade de shp2
WO2020185532A1 (en) 2019-03-08 2020-09-17 Incyte Corporation Methods of treating cancer with an fgfr inhibitor
KR102200032B1 (ko) * 2019-03-13 2021-01-08 전남대학교산학협력단 호흡기 질환의 예방 또는 치료용 조성물
US11591329B2 (en) 2019-07-09 2023-02-28 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
CA3150434A1 (en) 2019-08-09 2021-02-18 Incyte Corporation Salts of a pd-1/pd-l1 inhibitor
IL291471B2 (en) 2019-09-30 2025-04-01 Incyte Corp Pyrimido[3,2–D]pyrimidine compounds as immunomodulators
US12122767B2 (en) 2019-10-01 2024-10-22 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
EP4045151A1 (en) 2019-10-14 2022-08-24 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
US11566028B2 (en) 2019-10-16 2023-01-31 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
JP2023500395A (ja) 2019-11-11 2023-01-05 インサイト・コーポレイション Ｐｄ－１／ｐｄ－ｌ１阻害剤の塩及び結晶形態
EP4069695A1 (en) 2019-12-04 2022-10-12 Incyte Corporation Derivatives of an fgfr inhibitor
CA3163875A1 (en) 2019-12-04 2021-06-10 Incyte Corporation Tricyclic heterocycles as fgfr inhibitors
WO2021146424A1 (en) 2020-01-15 2021-07-22 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
AU2021230385A1 (en) 2020-03-06 2022-09-22 Incyte Corporation Combination therapy comprising AXL/MER and PD-1/PD-L1 inhibitors
TW202233616A (zh) 2020-11-06 2022-09-01 美商英塞特公司 用於製備ｐｄ－１／ｐｄ－ｌ１抑制劑以及其鹽及結晶形式之方法
US11760756B2 (en) 2020-11-06 2023-09-19 Incyte Corporation Crystalline form of a PD-1/PD-L1 inhibitor
US11780836B2 (en) 2020-11-06 2023-10-10 Incyte Corporation Process of preparing a PD-1/PD-L1 inhibitor
US12065494B2 (en) 2021-04-12 2024-08-20 Incyte Corporation Combination therapy comprising an FGFR inhibitor and a Nectin-4 targeting agent
CA3220155A1 (en) 2021-06-09 2022-12-15 Incyte Corporation Tricyclic heterocycles as fgfr inhibitors
WO2022261160A1 (en) 2021-06-09 2022-12-15 Incyte Corporation Tricyclic heterocycles as fgfr inhibitors
CN115960121B (zh) * 2022-10-27 2025-09-12 南通药明康德医药科技有限公司 一种合成1-(3-氧杂丁环烷基)-1h-吡唑-4-硼酸频哪醇酯的方法
KR20250135111A (ko) * 2024-03-05 2025-09-12 한국생명공학연구원 피리딘계 화합물을 유효성분으로 함유하는 염증성 질환 또는 자가면역질환의 예방 또는 치료용 약학적 조성물

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2004126671A (ru) 2002-02-06 2005-04-10 Вертекс Фармасьютикалз Инкорпорейтед (Us) Гетероарилсоединения, полезные в качестве ингибиторов gsk-3
GB0206860D0 (en) 2002-03-22 2002-05-01 Glaxo Group Ltd Compounds
WO2003093297A2 (en) * 2002-05-03 2003-11-13 Exelixis, Inc. Protein kinase modulators and methods of use
SE0202429D0 (sv) * 2002-08-14 2002-08-14 Astrazeneca Ab Novel Compounds
JP2006516626A (ja) 2003-01-28 2006-07-06 スミスクライン ビーチャム コーポレーション 化学的化合物
JP2006520794A (ja) 2003-03-21 2006-09-14 スミスクライン ビーチャム コーポレーション 化合物
SI1784396T1 (sl) 2004-08-26 2011-03-31 Pfizer S pirazolom substituirane aminoheteroarilne spojine kot zaviralci protein-kinaze
WO2006063167A1 (en) 2004-12-08 2006-06-15 Smithkline Beecham Corporation 1h-pyrrolo[2,3-b]pyridines
US7872031B2 (en) 2006-03-22 2011-01-18 Vertex Pharmaceuticals Incorporated c-MET protein kinase inhibitors
CA2654358A1 (en) 2006-06-22 2007-12-27 Biovitrum Ab (Publ) Pyridine and pyrazine derivatives as mnk kinase inhibitors
EP1900727A1 (en) 2006-08-30 2008-03-19 Cellzome Ag Aminopyridine derivatives as kinase inhibitors
GB0619342D0 (en) 2006-09-30 2006-11-08 Vernalis R&D Ltd New chemical compounds
GB0625659D0 (en) 2006-12-21 2007-01-31 Cancer Rec Tech Ltd Therapeutic compounds and their use
KR100979439B1 (ko) 2008-04-10 2010-09-02 한국화학연구원 신규 피라졸 및 벤즈옥사졸 치환된 피리딘 유도체 또는이의 약학적으로 허용가능한 염, 이의 제조방법 및 이를유효성분으로 함유하는 이상세포 성장 질환의 예방 및치료용 약학적 조성물

Also Published As

Publication number Publication date
WO2009053737A3 (en) 2009-07-30
IL205108A0 (en) 2010-11-30
AU2008315746A1 (en) 2009-04-30
CO6270364A2 (es) 2011-04-20
CL2008003188A1 (es) 2009-11-27
TW200920367A (en) 2009-05-16
EP2215085A2 (en) 2010-08-11
JP2011500778A (ja) 2011-01-06
ECSP10010197A (es) 2010-06-29
CN101910158A (zh) 2010-12-08
ATE523508T1 (de) 2011-09-15
CA2703653A1 (en) 2009-04-30
AR069078A1 (es) 2009-12-30
UY31430A1 (es) 2009-05-29
US20090118305A1 (en) 2009-05-07
MX2010004491A (es) 2010-06-21
EP2215085B1 (en) 2011-09-07
US8017611B2 (en) 2011-09-13
KR20100089090A (ko) 2010-08-11
WO2009053737A2 (en) 2009-04-30

Similar Documents

Publication Publication Date Title
PE20091116A1 (es) Derivados de piridina y pirazina como inhibidores de tirosina quinasas
PE20080548A1 (es) Derivados de [4,5']bipirimidinil-6,4'-diamina como inhibidores de cinasa de proteina
UY28892A1 (es) Inhibidores selectivos de la enzima dipeptidilpeptidasa-iv (dpp-iv) composiciones farmaceuticas de las mismas y su uso terapeutico
SE0402735D0 (sv) Novel compounds
CY1114925T1 (el) Χορηγηση αναστολεων διπεπτιδυλοπεπτιδασης
PE20090511A1 (es) Imidazopiridinonas
UY29246A1 (es) Nuevos compuestos
ECSP077985A (es) Inhibidores de proteina cinasa derivados de pirrol (2,3-b) piridina
EA200501928A1 (ru) Пирролодигидроизохинолины как ингибиторы pde10
CL2010001486A1 (es) Compuestos derivados de [1,2,4]triazolo[1,5-a]piridina, inhibidores de jak; composicion farmaceutica; kit farmaceutico; su uso en el tratamiento de enfermedades tales como cancer, diabetes, enfermedad de alzheimer, enfermedad hepatica, trastornos del snc, entre otras.
PA8496301A1 (es) Inhibidores de metaloproteasas.
UY28885A1 (es) 4-fenilamino-quinazolin-6-il-amidas referencia cruzada a solicitud(es) relacionada(s)
MX2010002179A (es) Composicion para el tratamiento de enfermedades neoplasicas.
PE20110560A1 (es) NUEVOS DERIVADOS DE TRIAZOLO[4,3-a]PIRIDINA, SU PROCEDIMIENTO DE PREPARACION, SU APLICACION COMO MEDICAMENTOS, COMPOSICIONES FARMACEUTICAS Y NUEVA UTILIZACION PARTICULARMENTE COMO INHIBIDORES DE MET
PE20090944A1 (es) PIRIMIDINAS BICICLICAS FUSIONADAS COMO INHIBIDORES DE LA VIA Pi3K/AKT
ECSP10010361A (es) Derivados de piridazinona
NO20081942L (no) Karbamoylbenzotriazolderivater som inhibitorer av lipaser og fosfolipaser
PE20090110A1 (es) Compuestos macrociclicos derivados de amina como agentes inhibidores de hsp90
UY30397A1 (es) Derivados sustituidos de la (3as, 7as)-1,3a,4,5,6,7-hexahidro-3h-benzoimidazol-2-ona, proceso de preparacion, composiciones conteniéndolos yaplicaciones
UY30393A1 (es) Derivados sustituidos de la 1-piperidin-1-il-1,3-dihidro-2h-benzimidazol-2-ona, composiciones farmacéuticas conteniéndolos, procesos de preparación y aplicaciones
UA101162C2 (ru) Производные индол-2-она, двузамещенные в положении 3, их получение и применение в терапии
ECSP099506A (es) Derivados de 2-quinolinona y 2 quinoxalinona y su utilización como agentes anti bacterianos
PE20080207A1 (es) DERIVADOS DE 1-N-AMINO-2-IMIDAZOLIDINONAS COMO INHIBIDORES DEL CANAL DE POTASIO Kv1.5
NO20082130L (no) 3-Amino-1-arylpropylindoler og aza-substituerte indoler
PE20081261A1 (es) DERIVADOS DEL FLUORENO COMO INHIBIDORES DE LA PROTEINA CHAPERONA Hsp90 Y COMPOSICIONES QUE LOS CONTIENEN

Legal Events

Date Code Title Description
FC Refusal